Bone-Density Drug Could Lower Colorectal Cancer Risk

Israeli and American researchers reported this week in the Journal of Clinical Oncology on a new study suggesting that postmenopausal women taking alendronate (Fosamax) were less likely to develop colorectal cancer. The results are “intriguing,” said Eric Jacobs, the American Cancer Society’s Strategic Director of Pharmacoepidemiology in Reuters Health. However, Jacobs cautioned, a recent large United…  Read More